Immunization with a Recombinant Envelope Protein (rgp90) of EIAV Produces a Spectrum of Vaccine Efficacy Ranging from Lack of Clinical Disease to Severe Enhancement
- 1 May 1998
- Vol. 245 (1) , 151-162
- https://doi.org/10.1006/viro.1998.9142
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Studies of High Doses of a Human Immunodeficiency Virus Type 1 Recombinant Glycoprotein 160 Candidate Vaccine in HIV Type 1-Seronegative HumansAIDS Research and Human Retroviruses, 1994
- Enhancement of EIAV Replication and Disease by Immunization with a Baculovirus-Expressed Recombinant Envelope Surface GlycoproteinVirology, 1994
- Reduced Virus Load in Rhesus Macaques Immunized with Recombinant gp160 and Challenged with Simian Immunodeficiency VirusAIDS Research and Human Retroviruses, 1994
- Summary Report: Workshop on the Potential Risks of Antibody-Dependent Enhancement in Human HIV Vaccine TrialsAIDS Research and Human Retroviruses, 1993
- Equine infectious anemia virus (EIAV) Humoral responses of recipient ponies and antigenic variation during persistent infectionArchiv für die gesamte Virusforschung, 1990
- Do antibodies enhance the infection of cells by HIV?Nature, 1989
- WILL ANTIBODY-DEPENDENT ENHANCEMENT OF HIV-1 INFECTION BE A PROBLEM WITH AIDS VACCINES?The Lancet, 1988
- ANTIBODY-DEPENDENT ENHANCEMENT OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTIONThe Lancet, 1988
- Antibody-Dependent Enhancement of Viral InfectivityPublished by Elsevier ,1986
- Antibody-mediated enhancement of disease in feline infectious peritonitis: Comparisons with dengue hemorrhagic feverComparative Immunology, Microbiology and Infectious Diseases, 1981